Search

KR-20260065781-A - Composition for preventing or treating liver-related diseases comprising Citrus limon L juice as an active ingredient

KR20260065781AKR 20260065781 AKR20260065781 AKR 20260065781AKR-20260065781-A

Abstract

The objective of the present invention is to provide a composition for the prevention or treatment of liver-related diseases comprising lemon ( Citrus limon L) juice as an active ingredient. When lemon juice was administered in a CCl4- induced acute liver injury in Wistar rats model, the rats' body weight, liver weight, and liver index were measured, and it was confirmed that the rats' body weight increased and their liver weight and liver index recovered. In addition, to measure the hepatoprotective effect of lemon juice, blood liver enzymes ALP, Gamma-GT, ALAT, ASAT, direct bilirubin, and total plasma bilirubin were measured, and all were found to decrease, confirming that it has a hepatoprotective effect. Furthermore, histological confirmation of the hepatoprotective effect of lemon juice revealed significant recovery, which can be usefully applied in related businesses.

Inventors

  • 김봉이
  • 오사마 베코우치
  • 소울리만 암라니
  • 모하메드 달리

Assignees

  • 경희대학교 산학협력단

Dates

Publication Date
20260511
Application Date
20260427

Claims (10)

  1. In a food composition for the prevention and improvement of liver fibrosis comprising lemon ( Citrus limon ) juice as an active ingredient, A composition in which the above lemon juice contains 25.23 mg of total polyphenols and 12.75 mg of total flavonoids per 1 g of lemon juice.
  2. A composition according to claim 1, wherein the lemon juice comprises 3.12% eriodictyol, 5.69% rutin, 13.88% hesperidin, and 18.43% isorhamnetin.
  3. The composition of claim 1, wherein the composition reduces ALP (alkaline phosphatase), G-GT (gamma-glutamyl transferase), ALAT (alanine transaminase), ASAT (aspartate transaminase), direct bilirubin, and total plasma bilirubin.
  4. In claim 1, the composition is one that improves a liver damaged by hepatotoxicity.
  5. A composition according to claim 4, wherein the liver toxicity is caused by insecticides, carbon tetrachloride, chloroform, or trichloroethylene.
  6. In a feed composition for the prevention and improvement of liver fibrosis comprising lemon ( Citrus limon ) juice as an active ingredient, A composition in which the above lemon juice contains 25.23 mg of total polyphenols and 12.75 mg of total flavonoids per 1 g of lemon juice.
  7. In a pharmaceutical composition for the prevention and treatment of liver fibrosis comprising lemon ( Citrus limon ) juice as an active ingredient, A composition in which the above lemon juice contains 25.23 mg of total polyphenols and 12.75 mg of total flavonoids per 1 g of lemon juice.
  8. A method for improving serum ALP ( alkaline phosphatase), G-GT (gamma-glutamyl transferase), ALAT (alanine transaminase), ASAT (aspartate transaminase), direct bilirubin, and total plasma bilirubin levels, comprising the step of administering a composition containing lemon (Citrus limon) juice as an active ingredient to individuals other than humans.
  9. In claim 8, the method wherein the individual is an individual with liver damage induced by hepatotoxicity.
  10. In claim 9, the method wherein the liver toxicity is caused by insecticides, carbon tetrachloride, chloroform, or trichloroethylene.

Description

Composition for preventing or treating liver-related diseases comprising lemon juice as an active ingredient The object of the present invention is to provide a composition for the prevention or treatment of liver-related diseases comprising lemon ( Citrus limon L) juice as an active ingredient. Lemons are native to the Himalayas and thrive in relatively cool climates with little variation. They are widely cultivated in Italy, Spain, California in the United States, and Australia, but those grown along the Mediterranean coast are of the highest quality. It has a strong sour taste due to its high content of vitamin C and citric acid. Lemon oil is extracted from the peel and used as an ingredient in beverages, perfumes, and lemonade, while the juice is used as an ingredient in beverages, vinegar, and cosmetics, and is also used as a flavoring when making confectionery. More than 80–90% of ingested ethanol is metabolized in the liver, where it is oxidized to acetaldehyde. Many of the toxic effects of ethanol on the liver are explained by oxidative stress caused by ethanol metabolism. Ethanol or its metabolites cause auto-oxidation in hepatocytes and lead to hepatitis by acting as pro-oxidative factors or by reducing antioxidant levels. The association between lipid oxidation and membrane damage is a key characteristic of ethanol-induced liver injury. Excessive alcohol consumption and drug-induced liver injury cause liver fibrosis, serving as the first link in the chain leading from liver cirrhosis to liver cancer. However, modern individuals consistently consume alcohol for stress, social life, and pleasure, and take medications that induce liver damage due to various diseases. Consequently, there is an urgent need to develop materials capable of protecting the liver. While various hangover remedies are available on the market, very few materials have been developed into pharmaceuticals with recognized significant efficacy. Therefore, developing new liver-protective materials into food or pharmaceutical products would benefit public health and lead to industrial success. Accordingly, while researching lemons, the inventors confirmed that lemons protect liver cells and treat liver-related diseases, and thus completed the present invention. Figure 1 is the result of analyzing the active ingredients of the lemon juice of the present invention by HPLC-MS. Figure 2 is a figure confirming the structure of four types of phenolic compounds contained in the lemon juice of the present invention. Figure 3 shows the recovery of body weight, liver weight, and liver index when lemon juice was administered to a liver-damaged mouse model (liver fibrosis). Figure 4 shows the liver enzyme levels when lemon juice is administered to a mouse model of liver damage (liver fibrosis). Figure 5 shows the liver histopathological changes when lemon juice is administered to a liver injury mouse model (liver fibrosis). Hereinafter, the present invention will be described in detail with reference to the attached drawings and embodiments thereof. However, the following embodiments are presented as examples of the present invention, and if it is determined that a detailed description of a technology or configuration well known to those skilled in the art may unnecessarily obscure the essence of the present invention, such detailed description may be omitted, and the present invention is not limited by this. The present invention is capable of various modifications and applications within the scope of the claims set forth below and the equivalent scope interpreted therefrom. Furthermore, the terminology used in this specification is used to appropriately describe preferred embodiments of the present invention, and may vary depending on the intent of the user or operator, or the conventions of the field to which the present invention belongs. Accordingly, the definitions of these terms should be based on the content throughout this specification. Throughout the specification, when a part is described as "comprising" a certain component, this means that, unless specifically stated otherwise, it does not exclude other components but may include additional components. All technical terms used in this invention, unless otherwise defined, are used in the sense generally understood by those skilled in the art in the relevant field of this invention. Furthermore, while preferred methods or feeds are described herein, similar or equivalents are also included within the scope of this invention. The contents of all publications cited as references in this specification are incorporated into this invention. The term "prevention" as used in the present invention may refer to any act of suppressing or delaying the onset of liver-related diseases by administering a pharmaceutical composition for the prevention or treatment of liver disease according to the present invention to an individual. The term "treatment" as used in the present invention may mean any